Trump announces trade deal with EU following months of negotiations
WILMINGTON, Mass. - Charles River Laboratories International, Inc. (NYSE: CRL), a $6.8 billion market cap research organization with annual revenues exceeding $4 billion, and CHDI Foundation, Inc. have renewed their partnership to further Huntington’s disease (HD) therapeutic research, marking two decades of joint efforts. According to InvestingPro data, Charles River maintains a "Good" overall financial health score, positioning it well for this extended collaboration that will leverage the company’s global network to bolster CHDI’s drug discovery and development programs.
Since 2005, Charles River and CHDI have been at the forefront of HD research, a hereditary neurological disorder. The extended agreement announced today aims to integrate a wider range of Charles River’s services into CHDI’s research initiatives. The services encompass various disciplines, including integrated drug discovery, stem cell research, high-throughput screening, computational chemistry, pharmacokinetics, and safety pharmacology. InvestingPro analysis shows 12 analysts have recently revised their earnings expectations upward for the upcoming period, suggesting growing confidence in the company’s research-driven business model.
Shannon M. Parisotto, Corporate Executive Vice President at Charles River, expressed pride in the longstanding partnership with CHDI and optimism for the future of HD research. The collaborative efforts have led to the development of novel drug targets, translational research models, and preclinical evaluations of therapeutic candidates, resulting in 15 patent applications for new compounds.
Robert Pacifici, Ph.D., Chief Scientific Officer at CHDI, highlighted the value of Charles River’s scientific and technical contributions over the years and looked forward to deepening the collaboration to accelerate benefits for HD patients. David Fischer, Ph.D., Chief Technology Officer at Charles River, echoed this sentiment, emphasizing the team’s commitment to advancing HD treatment research.
The collaboration has also contributed to the broader HD drug discovery community, which now includes over 50 pharmaceutical and biotech companies. Furthermore, CHDI has agreed to share data with Charles River’s learning algorithms, contributing to the industry’s most extensive dataset while ensuring responsible data usage and protection.
The partnership’s renewal is based on a press release statement and reflects Charles River’s and CHDI’s dedication to developing therapies for Huntington’s disease, aiming to make a significant impact on the lives of those affected by the condition. Based on InvestingPro’s Fair Value analysis, Charles River appears undervalued at current levels, with analysts predicting profitability this year despite recent challenges. For deeper insights into Charles River’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Charles River Laboratories International Inc. reported its first-quarter 2025 earnings, surpassing analyst expectations with an earnings per share (EPS) of $2.34, exceeding the forecast of $2.09. The company also reported revenue of $984.2 million, which was higher than the anticipated $941.47 million, despite marking a 2.7% year-over-year decline. Following these results, Charles River raised its full-year guidance, projecting an EPS range of $9.30 to $9.80. Additionally, Deutsche Bank increased its price target for Charles River to $180, citing the company’s consistent performance and strategic moves to realign its cost structure. Evercore ISI also upgraded Charles River’s stock rating to Outperform with a price target of $170, following the company’s first-quarter earnings release and a cooperation agreement with Elliott Management. Redburn-Atlantic upgraded Charles River to Buy, noting an improvement in demand in its Discovery and Safety Assessment business, and set a price target of $182. These developments reflect a positive outlook on Charles River’s growth trajectory and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.